NRX Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
NRXP$2.380.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
PART I FINANCIAL INFORMATION
ITEM 1. Financial Statements
NRX PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,443 | $4,595 |
| Prepaid expenses and other current assets | 1,859 | 2,289 |
| Total current assets | 3,302 | 6,884 |
| Other assets | 349 | 431 |
| Total assets | $3,651 | $7,315 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $4,130 | $4,632 |
| Accrued and other current liabilities | 10,149 | 4,714 |
| Accrued clinical site costs | 379 | 524 |
| Convertible note payable and accrued interest – short term | 1,246 | 9,161 |
| Insurance loan payable | 320 | — |
| Warrant liabilities | 5,639 | 17 |
| Total current liabilities | 21,863 | 19,048 |
| Convertible note payable and accrued interest – long term | 5,011 | — |
| Total liabilities | $26,874 | $19,048 |
| Commitments and Contingencies (Note 8) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.001 par value, 50,000,000 shares authorized; | $— | $— |
| Series A convertible preferred stock, $0.001 par value, 12,000,000 shares authorized; 0 and 3,000,000 shares issued and outstanding at December 31, 2024 and 2023, respectively | — | 3 |
| Common stock, $0.001 par value, 500,000,000 shares authorized; 14,591,505 and 8,391,956 shares issued and outstanding at December 31, 2024 and 2023, respectively | 15 | 8 |
| Additional paid-in capital | 255,035 | 241,406 |
| Accumulated other comprehensive loss | — | (3) |
| Accumulated deficit | (278,273) | (253,147) |
| Total stockholders’ deficit | (23,223) | (11,733) |
| Total liabilities and stockholders' deficit | $3,651 | $7,315 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.